Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.

Date publication

juillet 2009

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BEDENNE Laurent , Pr BOUCHE Olivier , Pr BRONOWICKI Jean-Pierre

Tous les auteurs :
Barbare JC, Bouché O, Bonnetain F, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Cattan S, Lemoine A, Blanc JF, Bronowicki JP, Zarski JP, Cazorla S, Gargot D, Thevenot T, Diaz E, Bastie A, Aparicio T, Bedenne L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/19303768

Résumé

A previous study reported a significant survival benefit for octreotide compared with no treatment in patients with advanced hepatocellular carcinoma (HCC). This was investigated further in this multicentre study.

Mots clés

Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Hormonal, adverse effects, Carcinoma, Hepatocellular, drug therapy, Double-Blind Method, Drug Administration Schedule, Female, Humans, Liver Neoplasms, drug therapy, Male, Middle Aged, Octreotide, adverse effects, Quality of Life, Survival Analysis, Treatment Outcome

Référence

Eur. J. Cancer. 2009 Jul;45(10):1788-97